160 related articles for article (PubMed ID: 22933339)
21. A simple test for independent censoring under the proportional hazards model.
Lee SY; Wolfe RA
Biometrics; 1998 Sep; 54(3):1176-82. PubMed ID: 9840972
[TBL] [Abstract][Full Text] [Related]
22. Power comparisons for group sequential tests with nonparametric statistics in case of nonproportional hazards.
Demirhan H; Demirhan YP; Bacanli S
J Biopharm Stat; 2013 Mar; 23(2):447-60. PubMed ID: 23437950
[TBL] [Abstract][Full Text] [Related]
23. Bootstrap test for proportional hazard assumption on time-independent systematic effects of longevity data.
Casellas J
J Anim Breed Genet; 2011 Apr; 128(2):100-4. PubMed ID: 21385224
[TBL] [Abstract][Full Text] [Related]
24. The type I error and power of non-parametric logrank and Wilcoxon tests with adjustment for covariates--a simulation study.
Jiang H; Symanowski J; Paul S; Qu Y; Zagar A; Hong S
Stat Med; 2008 Dec; 27(28):5850-60. PubMed ID: 18759373
[TBL] [Abstract][Full Text] [Related]
25. Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach.
Rondeau V; Michiels S; Liquet B; Pignon JP
Stat Med; 2008 May; 27(11):1894-910. PubMed ID: 18069745
[TBL] [Abstract][Full Text] [Related]
26. Modeling dropout from adverse event data: impact of dosing regimens across pregabalin trials in the treatment of generalized anxiety disorder.
Lalovic B; Hutmacher M; Frame B; Miller R
J Clin Pharmacol; 2011 May; 51(5):706-18. PubMed ID: 20663989
[TBL] [Abstract][Full Text] [Related]
27. Detection of multiple change points in a Weibull accelerated failure time model using sequential testing.
Gierz K; Park K
Biom J; 2022 Mar; 64(3):617-634. PubMed ID: 34873728
[TBL] [Abstract][Full Text] [Related]
28. Analysis of time to event outcomes in randomized controlled trials by generalized additive models.
Argyropoulos C; Unruh ML
PLoS One; 2015; 10(4):e0123784. PubMed ID: 25906075
[TBL] [Abstract][Full Text] [Related]
29. Interim analysis on survival data: its potential bias and how to repair it.
van Houwelingen HC; van de Velde CJ; Stijnen T
Stat Med; 2005 Sep; 24(18):2823-35. PubMed ID: 16025546
[TBL] [Abstract][Full Text] [Related]
30. Reformulating the hazard ratio to enhance communication with clinical investigators.
Moser BK; McCann MH
Clin Trials; 2008; 5(3):248-52. PubMed ID: 18559414
[TBL] [Abstract][Full Text] [Related]
31. Weighted win loss approach for analyzing prioritized outcomes.
Luo X; Qiu J; Bai S; Tian H
Stat Med; 2017 Jul; 36(15):2452-2465. PubMed ID: 28343373
[TBL] [Abstract][Full Text] [Related]
32. Bayesian analysis for monotone hazard ratio.
Kim Y; Park JK; Kim G
Lifetime Data Anal; 2011 Apr; 17(2):302-20. PubMed ID: 20635203
[TBL] [Abstract][Full Text] [Related]
33. Prediction of cumulative incidence function under the proportional hazards model.
Cheng SC; Fine JP; Wei LJ
Biometrics; 1998 Mar; 54(1):219-28. PubMed ID: 9544517
[TBL] [Abstract][Full Text] [Related]
34. Are non-constant rates and non-proportional treatment effects accounted for in the design and analysis of randomised controlled trials? A review of current practice.
Jachno K; Heritier S; Wolfe R
BMC Med Res Methodol; 2019 May; 19(1):103. PubMed ID: 31096924
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity of the hazard ratio to nonignorable treatment assignment in an observational study.
Mitra N; Heitjan DF
Stat Med; 2007 Mar; 26(6):1398-414. PubMed ID: 16779876
[TBL] [Abstract][Full Text] [Related]
36. A single-index threshold Cox proportional hazard model for identifying a treatment-sensitive subset based on multiple biomarkers.
He Y; Lin H; Tu D
Stat Med; 2018 Oct; 37(23):3267-3279. PubMed ID: 29869381
[TBL] [Abstract][Full Text] [Related]
37. Analysis of time-to-event data using a flexible mixture model under a constraint of proportional hazards.
Liu GF; Liao JJZ
J Biopharm Stat; 2020 Sep; 30(5):783-796. PubMed ID: 32589509
[TBL] [Abstract][Full Text] [Related]
38. A likelihood and resampling based approach to dichotomizing a continuous biomarker in medical research.
Su M; Fang L; Su Z
J Biopharm Stat; 2013 May; 23(3):637-47. PubMed ID: 23611200
[TBL] [Abstract][Full Text] [Related]
39. Statistical inference for cancer trials with treatment switching.
Shao J; Chang M; Chow SC
Stat Med; 2005 Jun; 24(12):1783-90. PubMed ID: 15900586
[TBL] [Abstract][Full Text] [Related]
40. Estimating and testing for center effects in competing risks.
Katsahian S; Boudreau C
Stat Med; 2011 Jun; 30(13):1608-17. PubMed ID: 21341296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
